Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population
29 Jan 2025
Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Radiotherapy in Kharkiv
Prostate cancer
Rectal cancer
Breast cancer
Radiobiology of hypofractionation
Physics of hypofractionated radiotherapy
Palliative radiotherapy
The economics of hypofractionated radiotherapy for prostate cancer
State of radiotherapy in Ukraine